RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

05/24/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit

May 24, 2022

5/17/22 – RespireRx Pharmaceuticals Inc. Announces RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics

May 17, 2022

5/16/22 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

May 16, 2022

WATCH: RespireRx Interim CEO Arnold Lippa Presents Data at 2022 GRI Virtual Conference

WATCH: RespireRx Interim CEO Arnold Lippa Discusses Provisional Patent Application for a Novel Lipid-Based Formulation Technology (LFT)